Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link

Disclaimer: Early release articles are not considered as final versions. Any changes will be reflected in the online version in the month the article is officially released.

Volume 30, Number 8—August 2024
Dispatch

Hepatitis B Virus Reactivation After Switch to Cabotegravir/Rilpivirine in Patient with Low Hepatitis B Surface Antibody

Eisuke Adachi1Comments to Author , Ayako Sedohara1, Kotaro Arizono, Kazuaki Takahashi, Amato Otani, Yoshiaki Kanno, Makoto Saito, Michiko Koga, and Hiroshi Yotsuyanagi
Author affiliation: The University of Tokyo, Tokyo, Japan

Main Article

Table 1

Laboratory values over time of a person in Japan with HIV after diagnosis of an acute HBV infection, from diagnosis to 12 years*

Time from HBV diagnosis 0 mo 1 mo 3 mo 9 mo 5 y 6 y 8 y 12 y
ART regimen

TDF/FTC+LPV/RTV
TDF/FTC
TDF/FTC
TDF/FTC
TDF/FTC
TDF/FTC
B/F/TAF
Laboratory values
Anti-HBs, IU/mL† 20.8 0.00 N/A 2.03 N/A 18.6 8.55 9.34
HBsAg, mIU/mL‡ 119,533 68,065 552 0.00 0.00 0.00 0.00 0.00
Anti-HBe, inhibition %§ Negative Negative Negative Negative Negative NA NA NA
HBeAg, S/CO¶ 1,840 1,290 2.5 Negative Negative NA NA NA
HBV DNA, log copies/mL >8.8 6.8 3.8 ND ND ND NA ND
ALT, U/L 418 937 8 17 23 17 57 66
Total bilirubin, mg/dL 0.3 0.5 0.5 0.5 0.7 0.3 0.4 0.4
HBcrAg, log U/mL# NA NA NA NA NA NA NA Negative

*ALT, alanine aminotransferase; anti-HBe, hepatitis B e-antibody; anti-HBs, hepatitis B surface antibody; ART, antiretroviral therapy; B/F/TAF, bictegravir/emtricitabine/tenofovir alafenamide; HBcrAg, hepatitis B core-related antigen; HBeAg, hepatitis B e-antigen; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; LPV/RTV, lopinavir/ritonavir; mIU, milli-IU; NA, not applicable; ND, not detected; RPV, rilpivirine; S/CO, signal-to-cutoff ratio; TDF/FTC, tenofovir disoproxil fumarate/emtricitabine †Cutoff value 10 IU/mL. ‡Cutoff value 10 mIU/mL. §Cutoff value 50% inhibition. ¶Cutoff value 1.0 S/CO. #Cutoff value 3.0 log U/mL.

Main Article

1These first authors contributed equally to this article.

Page created: June 28, 2024
Page updated: July 19, 2024
Page reviewed: July 19, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external